News about "PALOMA-2 study"

Johnson & Johnson Secures FDA Approval for Monthly RYBREVANT FASPRO Dosing in EGFR-Mutated Lung Cancer

Johnson & Johnson Secures FDA Approval for Monthly RYBREVANT FASPRO Dosing in EGFR-Mutated Lung Cancer

Simplified once-monthly schedule for RYBREVANT FASPRO matches bi-weekly efficacy, reduces clinic visits and maintains a strong safety profile.

PALOMA-2 Study | 18/02/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members